Agenus Inc. [NASDAQ: AGEN] gained 1.65% or 0.09 points to close at $5.56 with a heavy trading volume of 2504752 shares. The company report on July 8, 2021 that Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021.
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that Steven O’Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors.”.
The panel will take place on Wednesday, July 14, 2021, from 4:20 p.m. to 5:20 p.m. ET. The event will be webcast live and may be accessed on the Company’s website at https://investor.agenusbio.com/events-and-presentations.
It opened the trading session at $5.47, the shares rose to $5.61 and dropped to $5.40, the range by which the price of stock traded the whole day. The daily chart for AGEN points out that the company has recorded 58.40% gains over the past six months. However, it is still -122.4% lower than its most recent low trading price.
If we look at the average trading volume of 5.07M shares, AGEN reached to a volume of 2504752 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Agenus Inc. [AGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 19, 2019. The new note on the price target was released on April 22, 2019, representing the official price target for Agenus Inc. stock. Previously, the target price had yet another drop from $10 to $5, while H.C. Wainwright kept a Neutral rating on AGEN stock.
The Average True Range (ATR) for Agenus Inc. is set at 0.22, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 14.61.
Trading performance analysis for AGEN stock
Agenus Inc. [AGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.42. With this latest performance, AGEN shares gained by 5.70% in over the last four-week period, additionally plugging by 58.40% over the last 6 months – not to mention a rise of 49.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 63.79, with the RSI for the last a single of trading hit 60.74, and the three-weeks RSI is set at 65.50 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 4.74, while it was recorded at 5.47 for the last single week of trading, and 3.87 for the last 200 days.
Agenus Inc. [AGEN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Agenus Inc. [AGEN] shares currently have an operating margin of -340.25. Agenus Inc.’s Net Margin is presently recorded at -434.14.
Reflecting on the efficiency of the workforce at the company, Agenus Inc. [AGEN] managed to generate an average of -$543,170 per employee. Receivables Turnover for the company is 35.49 with a Total Asset Turnover recorded at a value of 0.27.Agenus Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.00.
An analysis of insider ownership at Agenus Inc. [AGEN]
There are presently around $645 million, or 52.50% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: BLACKROCK INC. with ownership of 14,251,912, which is approximately -1.83% of the company’s market cap and around 0.60% of the total institutional ownership; RTW INVESTMENTS, LP, holding 13,777,244 shares of the stock with an approximate value of $76.6 million in AGEN stocks shares; and STATE STREET CORP, currently with $70.49 million in AGEN stock with ownership of nearly 23.075% of the company’s market capitalization.
Positions in Agenus Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 72 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 16,901,060 shares. Additionally, 59 investors decreased positions by around 7,618,399 shares, while 28 investors held positions by with 91,439,647 shares. The mentioned changes placed institutional holdings at 115,959,106 shares, according to the latest SEC report filing. AGEN stock had 16 new institutional investments in for a total of 6,671,833 shares, while 18 institutional investors sold positions of 696,139 shares during the same period.